Terns Pharmaceuticals

Historical price data

Terns Pharmaceuticals is a publicly traded, clinical-stage biotech company with a mission to advance transformative medicines by reimagining known biology. Its core strategy involves selecting de-risked, clinically validated targets and applying innovative medicinal chemistry to develop potentially best-in-class small-molecule drugs. The company's most significant achievement is the advancement of TERN-701 for CML, which has culminated in a definitive acquisition agreement with Merck, validating its platform and pipeline. Terns operates with a focused, agile team and a culture designed to accelerate development timelines in high-need therapeutic areas.

A targeted development platform focused on selecting clinically validated biological mechanisms and applying innovative medicinal chemistry to create potentially best-in-class small-molecule therapies.

TERN-701 competes directly with Novartis's allosteric inhibitor asciminib in CML, requiring clear differentiation. In obesity/metabolic disease, the landscape is dominated by GLP-1 agonists from Novo Nordisk and Eli Lilly. Terns' asset-centric model competes for investment against broader platform technologies.